Notice2024-22069
Notice Pursuant to the National Cooperative Research and Production Act of 1993-The Customer Experience Hub
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 26, 2024
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 187 (Thursday, September 26, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 187 (Thursday, September 26, 2024)]
[Notices]
[Pages 78902-78903]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-22069]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--The Customer Experience Hub
Notice is hereby given that, on July 3, 2024, pursuant to section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), The Customer Experience Hub (``CX
Hub'') has filed written notifications simultaneously with the Attorney
General and the Federal Trade Commission disclosing changes in its
membership. The notifications were filed for the purpose of extending
the Act's provisions limiting the recovery of antitrust plaintiffs to
actual damages under specified circumstances. Specifically, Advanced
Functional Fabrics of America, Inc., Cambridge, MA; Alacura Medical
Transport Management, Inc., Dallas, TX; Amazon Web Services, Inc.,
Seattle, WA; AMPEL LLC dba AMPEL BioSolutions LLC, Charlottesville, VA;
Aptima, Inc., Woburn, MA; Avsana Labs, Inc., Dallas, TX; Axiom Space,
Inc., Houston, TX; Be Well Texas, San Antonio, TX; BetterAge,
Sunnyside, NY; Bexar County Hospital District dba University Health
System, San Antonio, TX; BioCytics, Inc., Huntersville, NC; Boyd
Biomedical, Inc., Lee, MA;
[[Page 78903]]
Carolina BioOncology Institute PLLC, Huntersville, NC; Clinicals Global
Pty Ltd., Fortitude Valley, AUSTRALIA; Cure Experience Service LLC, New
York, NY; DesignPlex Biomedical LLC, Fort Worth, TX; Detroit
Association of Black Organizations, Inc. (DABO), Detroit, MI;
DiversiTrials, Florence, KY; Dynocardia, Inc., Cambridge, MA; Echo
Investment Capital, Oklahoma City, OK; Elarex, Inc., Burlington,
CANADA; Emagine Solutions Technology LLC, Tucson, AZ; Essex Management
LLC, Rockville, MD; Esvyda!, Inc., Campbell, CA; Eztia Corp., Diamond
Bar, CA; Focused Ultrasound Foundation, Charlottesville, VA; Galen
Data, Inc., Houston, TX; GE Healthcare Technology & Innovation Center,
Niskayuna, NY; Gryphon Scientific LLC, Takoma Park, MD; IA
Collaborative Management Services LLC, Chicago, IL; Implementation
Science Center for Cancer Control Equity (ISCCCE), Boston, MA; InnoTech
Precision Medicine, Inc., Lowell, MA; Inter Astra Institute, McLean,
VA; Maternal Newborn Health Innovations, PBC (MNHI), Parsippany, NJ;
Maximus, Inc., McLean, VA; MediMergent LLC, Rockville, MD; Metronomic,
Inc., Chantilly, VA; Mid-Atlantic Permanente Medical Group, P.C.,
Rockville, MD; MitoChem Therapeutics, Inc., Charleston, SC; Namida Lab,
Inc., Fayetteville, AR; National Health Council, Inc., Washington, DC;
NKILT Therapeutics, Inc., Springfield, NJ; Northeastern University,
Boston, MA; OnKai, Inc., Boca Raton, FL; Parallax Advanced Research
Corp., Beavercreek, OH; Pediatric Moonshot, Marina del Rey, CA; Proov,
Erie, CO; Quorum Innovations LLC, Sarasota, FL; SANO Healthcare
Consultants LLC, Ontario, CA; SEQSTER PDM, Inc., San Diego, CA; Spring
Discovery, Inc., San Carlos, CA; Starling Medical, Inc., Houston, TX;
SubjectWell, Inc., Austin, TX; Synthesize Consulting Group, Woodbridge,
CANADA; Texas A&M University-Corpus Christi, Corpus Christi, TX; The
Emmes Company LLC, Rockville, MD; The Termeer Foundation, Boston, MA;
The University of Texas Health Science Center at Tyler, Tyler, TX;
Touch4Life, Clarksville, MD; Triple Ring Technologies, Inc., Newark,
CA; University of Connecticut Health Center, Farmington, CT; University
of Illinois, Chicago, IL; University of Illinois Urbana-Champaign,
Urbana, IL; University of Missouri System, Columbia, MO; University of
Texas Health Science Center at Houston, Houston, TX; University of
Texas Medical Branch at Galveston, Galveston, TX; University of Texas
Southwestern Medical Center, Dallas, TX; Washington Global Health
Alliance, Redmond, WA; Washington University in St. Louis, St. Louis,
MO; and Wiliam Marsh Rice University, Houston, TX, have been added as
parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and CX Hub intends to file additional
written notifications disclosing all changes in membership.
On January 11, 2024, CX Hub filed its original notification
pursuant to section 6(a) of the Act. The Department of Justice
published a notice in the Federal Register pursuant to section 6(b) of
the Act on April 16, 2024 (89 FR 26929).
The last notification was filed with the Department on April 17,
2024. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on June 21, 2024 (89 FR 52093).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-22069 Filed 9-25-24; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on September 26, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.